BioAge Labs has initiated Phase 2 testing of BGE-102, an oral NLRP3 inhibitor designed to reduce cardiovascular risk through suppression of inflammatory pathways. Phase 1 data demonstrated substantial reductions in high-sensitivity C-reactive protein with once-daily dosing, positioning the compound as a candidate for managing systemic inflammation linked to cardiovascular disease progression.
Key Points
- NLRP3 inhibition reduces hsCRP, a marker of systemic inflammation
- Oral, brain-penetrant formulation enables daily dose compliance
- Phase 2 will establish optimal dose for cardiovascular risk reduction
Longevity Analysis
Cardiovascular disease remains a primary driver of mortality and morbidity in aging populations. The NLRP3 inflammasome is a key regulator of sterile inflammation—the chronic, low-grade activation that accompanies aging and precedes clinical disease. By targeting this pathway pharmacologically, BGE-102 addresses a fundamental mechanism rather than managing symptoms downstream. The magnitude of hsCRP reduction in Phase 1 suggests potential to shift the inflammatory trajectory that accelerates vascular aging, though clinical outcomes remain to be established. Success would represent a meaningful addition to the limited pharmacologic tools available for primary prevention in asymptomatic at-risk individuals.
Original published by Longevity.Technology.